Bicizumab latest price inquiry and market trends in 2025

Bimekizumab is a new monoclonal antibody primarily used to treat moderate to severe plaque psoriasis (psoriasis). Psoriasis is a chronic autoimmune disease in which red, scaly patches appear on the patient's skin, seriously affecting the patient's quality of life and mental health. Bicizumab targets two cytokines, IL-17A and IL-17F, to effectively reduce the inflammatory response and improve skin lesions.

In China, bicizumab has obtained marketing approval, but it has not yet been included in medical insurance, which means that patients need to purchase it at their own expense. According to market information, the current price of bicizumab is approximately RMB 3 to 4,000 per box (160mg*1 tube). This price may pose a financial burden for many patients, especially in the case of long-term treatment. In addition, because domestic stocks are currently limited, patients may face supply shortages when accessing medications, further compounding treatment difficulties.

In contrast, overseas markets also provide the original drug of bicizumab, which is usually sold in packages of 160mg*2 tubes, and the price is about 40,000 to 50,000 yuan. Although the prices of overseas drugs are higher, there is still a certain market demand as some patients may prefer to choose imported drugs in order to obtain better therapeutic effects. However, this high cost is not easily affordable for most patients.

Clinical studies of bicizumab have shown that it has significant efficacy in improving psoriasis symptoms, and its administration is less frequent than traditional treatments, allowing patients to achieve greater convenience and compliance during treatment. Typically, patients will see significant improvement in their skin lesions within weeks of treatment with bicizumab, greatly improving their quality of life.

Reference materials:https://www.drugs.com/bimekizumab.html